NGM Biopharmaceuticals (NGM) PT Raised to $36 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts NGM Hot Sheet
Price: $1.54 --0%
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 16
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 16
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on NGM Biopharmaceuticals (NASDAQ: NGM) to $36.00 (from $25.00) while maintaining a Buy rating.
You May Also Be Interested In
- Principal Financial Group (PFG) PT Lowered to $112 at UBS
- Agilysys Inc (AGYS) PT Raised to $140 at Piper Sandler
- Clearwater Paper (CLW) PT Lowered to $22 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
